CAMBRIDGE - Nona Biosciences, a wholly-owned subsidiary of
Under the terms of the agreement, ModeX will have access to Nona Bioscience's fully human Harbour Mice platforms to accelerate discovery of monoclonal antibodies to be integrated into ModeX's MSTAR platform. This is intended to significantly reduce an often time-consuming step of the preclinical development process. The MSTAR platform is designed to layer multispecific functionality onto industry standard antibody designs to enable a much wider range of functionality and disease applicability. The collaboration aims to leverage each company's unique strengths to drive forward the discovery of cutting edge treatments.
'We are delighted to enter into this collaboration with ModeX Therapeutics,'
'We look forward to partnering with Nona Biosciences to accelerate and enhance our discovery of novel multispecific antibody constructs that our team can advance into clinical development,' said
About Nona Biosciences
Nona Biosciences (a wholly-owned subsidiary of
Harbour Mice generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) formats. Integrating Harbour Mice and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs.
About ModeX Therapeutics
ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency in fighting complex disease. The ModeX pipeline includes candidates against both solid and hematologic tumors, as well as several of the world's most pressing viral threats. Its founding team includes globally recognized medical innovators with proven track records of delivering breakthroughs for patients. ModeX is an
Contact:
Email: BD@nonabio.com
(C) 2023 Electronic News Publishing, source